To facilitate the design of nucleic acid therapeutic candidates, we provide comprehensive analysis by dividing the input sequences into K-mer nucleotide sequences of the desired lengths (ASO: 15-21 nt, siRNA: 19-25 nt) to predict their efficacy.

Only nucleotide sequences with a length of less than 500 are allowed.